$PETS

PETMED EXPRESS INC

PetMed Express, doing business as PetMeds and parent company of PetCareRx, is a direct-to-consumer retailer of pet medications, food and health and wellness products for dogs, cats and horses. It sells through PetMeds.com and PetCareRx.com, mobile apps, customer contact centers and the PetAssure broker network. Its products include prescription and generic medications, over-the-counter products, supplements, prescription and non-prescription food, treats and pet supplies. The company also provides pharmacy fulfillment, prescription verification, AutoShip options, customer support, telemedicine partnerships and employer pet-benefit programs. PetMed Express earns money by selling products directly to consumers and distributing products and wellness services through employer benefit programs. It also provides pharmacy services, including prescription fulfillment. Its pharmacies operate in Delray Beach, Florida, and Lynbrook, New York. The company is headquartered in Delray Beach, Florida.

No enriched coverage for $PETS in the last 7 days.

No SEC Form 4 filings for $PETS in the last 30 days.

See all $PETS insider activity →
Med

PetMed Express Inc (PETS) (Q2 2027) Earnings Call Highlights: New CEO Charts

PetMed Express (PETS) reported Q2 2027 net sales of $35.8M, down 19.4% YoY, with a net loss of $6.4M. New CEO Jeff Willard highlighted cost reductions, including a 32% drop in customer acquisition cost and a 52.3% cut in advertising expenses. The company has $11.4M in cash and no debt. Willard outlined a multiyear turnaround strategy focusing on brand repositioning, marketing efficiency, and customer retention. Gross margin fell to 27.4% due to product mix and lower rebates.

PETMED EXPRESS INC (PETS): PetMeds® Announces Second Quarter Financial Results

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PetMeds® Announces Second Quarter Financial Results Delray Beach, Florida, November 10, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026. Quarte

PETS sentiment & insider activity

Recent PETS coverage spans earnings, corporate actions and financial news.

What's driving PETS

AlphAI scores every news story that mentions PETS with an AI model for sentiment and relevance, and aggregates insider trades from PETMED EXPRESS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PETS

Score

PetMed Express Inc (PETS) (Q2 2027) Earnings Call Highlights: New CEO Charts

PetMed Express (PETS) reported Q2 2027 net sales of $35.8M, down 19.4% YoY, with a net loss of $6.4M. New CEO Jeff Willard highlighted cost reductions, including a 32% drop in customer acquisition cost and a 52.3% cut in advertising expenses. The company has $11.4M in cash and no debt. Willard outlined a multiyear turnaround strategy focusing on brand repositioning, marketing efficiency, and customer retention. Gross margin fell to 27.4% due to product mix and lower rebates.

$PETSMedEarnings

PETMED EXPRESS INC (PETS): PetMeds® Announces Second Quarter Financial Results

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PetMeds® Announces Second Quarter Financial Results Delray Beach, Florida, November 10, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026. Quarte

$PETSLowExec change· appointed

PETMED EXPRESS INC (PETS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective September 27, 2026, the Board of Directors of PetMed Express, Inc. (the “Company”) approved an amendment to the Pe

$PETSLowExec change· appointed

PETMED EXPRESS INC (PETS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution DELRAY BEACH, Fla., September 21, 2

PetMeds CEO Transition: Jeff Willard To Succeed Leslie Campbell

PetMed Express (PETS) named Jeff Willard as CEO and President, effective September 28, 2026. Willard succeeds Leslie Campbell, who will retire as Board Chair. Willard has 25 years of leadership experience in consumer and e-commerce. The company aims to return to profitability and growth. PETS stock traded between $1.57 and $4.10 in the past year, closing at $4.10 on Wednesday.

$PETSMedExec change· appointed

PETMED EXPRESS INC (PETS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement DELRAY BEACH, Fla., September 17, 2026 — PetMed Express, Inc., dba PetMeds and parent company of

PetMed Express (PETS) Q1 2027 Earnings Call Transcript

PetMed Express reported Q1 2027 net sales of $41M, down 19.9% YoY, with a net loss of $6.1M. Key highlights include a $37M sale-leaseback deal, a partnership with Rural King, and an unsolicited acquisition offer of $3 per share. Management emphasized expense management and new revenue channels. Net sales stabilized above $40M sequentially, despite prescription sales declines.

PetMed Express, Inc. Q1 2027 Earnings Call Summary

PetMed Express, Inc. reported a Q1 2027 earnings call focused on shifting customer acquisition to diversified B2B and white-label offerings, after completing an SAP ERP rollout and new call center platform. Management cited a 15% acquisition cost reduction, delivery times improved up to 2 days, and recurring auto-ship and memberships at 61.5% of gross sales. Net loss was $6.1 million. It also disclosed an unsolicited $3/share acquisition proposal and a pending $37 million sale-leaseback.

Related tickers